Resources search

Action from the grassroots to parliament : access to essential medicines gets an airing in Zambia

CHOTA, Lazarus
et al
January 2010

Expand view

The unique position of stakeholders participating in the Medicines Transparency Alliance Zambia, means that the group are able to initiate discussions at many levels from grassroots to parliament. This is of great value in highlighting critical issues about the lack of access to essential medicines experienced by many citizens in Zambia and makes progress towards finding some solutions

Medicines : corruption and pharmaceuticals

WORLD HEALTH ORGANIZATION (WHO)
December 2009

Expand view

This fact sheet gives a brief overview of the key facts regarding corruption in the pharmaceutical supply chain. It focuses on unethical practices in the medicines supply chain, factors contributing to pharmaceutical corruption, the impact of corruption, and the response of the WHO

The role of local manufacturers in improving access to essential medicines|Creating opportunities for the scale-up of local pharmaceutical production

MOHAMED, Nazeem
November 2009

Expand view

The local manufacturing of pharmaceuticals is a hotly contested issue in many countries. It runs to the heart of key concerns such as quality, availability, and price of medicines. Some of the arguments of the local manufacturers are set out in this article by one of the co-chairs of the Medicines Transparency Alliance Uganda Council and Chairman of the Uganda Pharmaceutical Manufacturer's Association (UPMA)

Survey of the quality of selected antimalarial medicines circulating in Madagascar, Senegal, and Uganda

UNITED STATES PHARMACOPEIA DRUG AND INFORMATION PROGRAM
November 2009

Expand view

This report focuses on three of 10 sub-Saharan countries that were covered by a study examining the quality of key antimalarial medicines. A total of 491 samples of anti-malarial medicines (both artemisinin-based combination therapy and sulfadoxine-pyrimethamine products) were collected from the public sector, the regulated private sector and the informal market in these three countries. The study revealed a high failure rate among sampled antimalarials in all three countries, based both on Minilab and full-compendial or quality control laboratory testing

Shifting allegiances in access to medicines : the Medicines Transparency Alliance in Ghana

CHETLEY, Andrew
DODOO, Alexander
OFORI-ADJEI, David
September 2009

Expand view

This article looks at the ideas that Medicines Transparency Alliance (MeTA) is testing, in order to achieve its long term goal to make high-quality essential medicines available and affordable to poor people who are currently unable to access them; and at how these ideas are being put into practice in Ghana. Ghana is one of the seven countries involved in the pilot phase of MeTA, the other countries are Jordan, Kyrgyzstan, Peru, the Philippines, Uganda and Zambia

Malaria treatment in Nigeria : the role of patent medicine vendors

OLADEPO, Oladimeji
et al
March 2009

Expand view

"This scoping study provides a quick assessment of the malaria treatment markets and the role played by patent medicine vendors in Nigeria, and offers ways to improve the regulation and provision of anti-malarial drugs. It documented the sources of drugs in the three states and people’s problems in getting access to appropriate treatment for malaria"

Safe medicines project - phase II : the Zambian case study

AFRICA FIGHTING MALARIA
March 2009

Expand view

This bulletin reports on the results of a study in which a range of antimalarial drugs were procured from private pharmacies, shops and kiosks within the urban and peri-urban areas of Lusaka, Zambia and tested to measure the active pharmaceutical ingredient content against internationally acceptable standards

Counterfeit drugs kill

INTERNATIONAL MEDICAL PRODUCTS ANTI-COUNTERFEITING TASKFORCE (IMPACT)
May 2008

Expand view

This leaflet describes how counterfeit medicines may endanger people's health because their quality is unpredictable. It also considers the challenges faced in combating counterfeit medicines and the role of the IMPACT coalition

Antimalarial drug quality in the most severely malarious parts of Africa - a six country study

BATE, Roger
et al
May 2008

Expand view

This article describes research conducted on a range of antimalarial drugs, procured from private pharmacies in urban and peri-urban areas in the major cities of six African countries which were subjected to semi-quantitative thin-layer chromatography (TLC) and dissolution testing to measure active pharmaceutical ingredient content against internationally acceptable standards

Public and private sector approaches to improving pharmaceutical quality in Bangladesh

KOSTERMANS, Kees
et al
March 2008

Expand view

"Low-cost high-quality drugs benefit society and helps provide pharmaceutical companies a competitive edge. This study presents the issues that must be considered to achieve these common objectives in Bangladesh and explores options that the Government and the local industry could pursue. "Previous efforts to improve the drug quality in Bangladesh focused, without much success, on stricter regulation of the public market. This paper addresses this issue from a more private sector approach. The existing quality and price of pharmaceuticals are analysed and alternative mechanisms are explored to improve the quality and cost competitiveness of Bangladesh’s pharmaceuticals domestically and internationally"

A model quality assurance system for procurement agencies : recommendations for quality assurance systems focusing on prequalification of products and manufacturers, purchasing, storage and distribution of pharmaceutical products

WORLD HEALTH ORGANIZATION (WHO)
2007

Expand view

This report is intended to assist organisations purchasing pharmaceutical products, vaccines or other health sector goods, or who are otherwise involved in the prequalification, purchasing, storage and distribution of such products. It addresses the general requirement for the quality assurance system that needs to be in place at all procurement agencies and sets out recommendations that these agencies should implement when evaluating product needs, assessing the products offered and the manufacturing and supply arrangements. It also describes principles of purchasing pharmaceutical products, how to receive and store them; good distribution practices; and monitoring and reassessment of products and contracted-out activities. This document was previously published as Annex 6 of the 40th Report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (Technical report 937, 2006).

A model quality assurance system for procurement agencies : recommendations for quality assurance systems focusing on prequalification of products and manufacturers, purchasing, storage and distribution of pharmaceutical products

WORLD HEALTH ORGANIZATION (WHO)
2007

Expand view

The long-term goal of these recommendations is the design and implementation of a uniform and harmonised system that will ensure procurement of pharmaceutical products of defined quality for supply to patients, based on a mutually recognised process of prequalification of products and manufacturers by means of product dossier evaluation and inspection of manufacturing sites. This document was previously published as Annex 6 of the WHO Technical Report Series No. 937, 2006

Anti-corruption in the health sector : preventing drug diversion through supply chain management

VIAN, Taryn
October 2006

Expand view

This case-based brief describes how the President’s Emergency Plan for AIDS Relief (the US PEPFAR initiative) and the related Supply Chain Management System (SCMS) Project are working to increase transparency and provide a secure, high-quality supply of HIV/AIDS drugs to developing countries in Africa and Asia. Drug supply is an essential component of health care systems, accounting for 10-30 percent of health care costs. Drugs can be expensive, and willingness to pay for drugs is high, creating the danger that employees will divert drugs for re-packaging and sale in the grey market, or for personal use

Processes and issues for improving access to medicines : the evidence base for domestic production and greater access to medicines

GUIMIER Jean-Marc Guimier
LEE, Evan
GRUPPER, Michel
2004

Expand view

This study addresses the question of whether access to medicines can be improved in sub-Saharan Africa by producing them locally. For this production to be sustainable, it must be both economically viable while meeting quality standards, and result in the improvement of access along one or more of the following dimensions: geographical accessibility, physical availability, affordability and acceptability

Pages

E-bulletin

Source e-bulletin on Disability and Inclusion

Subscribe to updates